Zhe Jiang Dayang Biotech Group Co., Ltd. (SHE:003017)
China · Delayed Price · Currency is CNY 26.50
-0.16 (-0.60%)
Jun 10, 2026, 3:04 PM CST
SHE:003017 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,059 | 1,030 | 900.31 | 912.24 | 1,048 | 772.51 |
Other Revenue | 15.72 | 15.72 | 9.64 | 7.22 | 10.43 | 10.7 |
| 1,075 | 1,045 | 909.96 | 919.45 | 1,058 | 783.21 | |
Revenue Growth (YoY) | 11.46% | 14.89% | -1.03% | -13.10% | 35.10% | 15.46% |
Cost of Revenue | 831.19 | 809.63 | 738.72 | 757.87 | 913.61 | 633.26 |
Gross Profit | 243.4 | 235.81 | 171.24 | 161.58 | 144.49 | 149.95 |
Selling, General & Admin | 87.39 | 85.49 | 74.93 | 75.1 | 65.94 | 63.34 |
Research & Development | 43.89 | 43.78 | 28.78 | 39.22 | 34.06 | 27.84 |
Other Operating Expenses | -4.7 | -6.44 | -7.06 | -7.22 | -7.69 | -7.72 |
Operating Expenses | 128.56 | 124.27 | 97.73 | 105.52 | 94.08 | 83.65 |
Operating Income | 114.85 | 111.54 | 73.5 | 56.06 | 50.41 | 66.3 |
Interest Expense | -4.09 | -4.29 | -6.77 | -6.14 | -5.48 | -2.77 |
Interest & Investment Income | 10.37 | 10.1 | 8.85 | 10.79 | 3.49 | 11.22 |
Currency Exchange Gain (Loss) | 0.09 | 0.09 | 1.57 | 1.13 | 2.74 | -0.48 |
Other Non Operating Income (Expenses) | 0.41 | 0.14 | -1.27 | -0.6 | -0.65 | -0.1 |
EBT Excluding Unusual Items | 121.63 | 117.58 | 75.88 | 61.24 | 50.51 | 74.17 |
Gain (Loss) on Sale of Investments | -0.89 | -1.46 | 0.36 | -1.48 | 0.71 | -0.32 |
Gain (Loss) on Sale of Assets | 2.03 | 2.05 | 0.09 | -0.17 | 3.41 | 0.12 |
Asset Writedown | -19.54 | -18.81 | -7.96 | -17.02 | -0.19 | -1.89 |
Other Unusual Items | 7.46 | 7.49 | 3.28 | 4.41 | 3 | 4.06 |
Pretax Income | 110.67 | 106.85 | 71.64 | 46.99 | 57.45 | 76.14 |
Income Tax Expense | 9.04 | 6.79 | 7.91 | -3.02 | -23.27 | 6.13 |
Earnings From Continuing Operations | 101.64 | 100.06 | 63.74 | 50.01 | 80.73 | 70.01 |
Minority Interest in Earnings | -0.26 | -0.21 | 0.01 | - | - | - |
Net Income | 101.38 | 99.85 | 63.75 | 50.01 | 80.73 | 70.01 |
Net Income to Common | 101.38 | 99.85 | 63.75 | 50.01 | 80.73 | 70.01 |
Net Income Growth | 33.10% | 56.64% | 27.48% | -38.05% | 15.31% | -23.58% |
Shares Outstanding (Basic) | 81 | 81 | 81 | 81 | 81 | 84 |
Shares Outstanding (Diluted) | 82 | 82 | 82 | 81 | 82 | 84 |
Shares Change (YoY) | 0.27% | 0.30% | 1.62% | -0.99% | -2.93% | 26.42% |
EPS (Basic) | 1.25 | 1.23 | 0.78 | 0.62 | 0.99 | 0.83 |
EPS (Diluted) | 1.23 | 1.21 | 0.78 | 0.62 | 0.99 | 0.83 |
EPS Growth | 32.74% | 56.16% | 25.44% | -37.43% | 18.79% | -39.55% |
Free Cash Flow | 11.35 | 83.72 | 2.74 | 78.8 | -12.76 | -128.59 |
Free Cash Flow Per Share | 0.14 | 1.02 | 0.03 | 0.98 | -0.16 | -1.53 |
Dividend Per Share | 0.600 | 0.600 | 0.300 | 0.736 | 0.143 | 0.429 |
Dividend Growth | 100.00% | 100.00% | -59.24% | 415.05% | -66.66% | - |
Gross Margin | 22.65% | 22.56% | 18.82% | 17.57% | 13.66% | 19.14% |
Operating Margin | 10.69% | 10.67% | 8.08% | 6.10% | 4.76% | 8.47% |
Profit Margin | 9.43% | 9.55% | 7.00% | 5.44% | 7.63% | 8.94% |
Free Cash Flow Margin | 1.06% | 8.01% | 0.30% | 8.57% | -1.21% | -16.42% |
EBITDA | 187.05 | 182.86 | 141.31 | 124.86 | 109.8 | 110.54 |
EBITDA Margin | 17.41% | 17.49% | 15.53% | 13.58% | 10.38% | 14.11% |
D&A For EBITDA | 72.2 | 71.32 | 67.81 | 68.81 | 59.39 | 44.24 |
EBIT | 114.85 | 111.54 | 73.5 | 56.06 | 50.41 | 66.3 |
EBIT Margin | 10.69% | 10.67% | 8.08% | 6.10% | 4.76% | 8.47% |
Effective Tax Rate | 8.16% | 6.35% | 11.04% | - | - | 8.05% |
Revenue as Reported | 1,075 | 1,045 | 909.96 | 919.45 | 1,058 | 783.21 |
Advertising Expenses | - | 1.04 | 0.65 | 0.42 | 0.06 | 4.09 |